1
|
Sourbier C, Massfelder T. Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett 2005; 240:170-82. [PMID: 16223565 DOI: 10.1016/j.canlet.2005.08.020] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2005] [Accepted: 08/31/2005] [Indexed: 12/27/2022]
Abstract
Parathyroid hormone-related protein (PTHrP), a polyprotein discovered in 1987, plays crucial roles not only in development and in various physiological events associated with normal life, but also in a number of pathological conditions such as cancer. PTHrP appears as the major causative agent in humoral hypercalcemia of malignancy (HHM) associated to a broad range of tumors. However, this is only one aspect of the multiple facets of PTHrP in cancer biology. Indeed, the complex growth factor-like properties of PTHrP has shed new light onto potential roles of this peptide in the regulation of tumor growth and invasion. Initial studies in breast, prostate and lung cancer and recent results in renal cell carcinoma (RCC) suggest such roles and highlight the therapeutic potential of PTHrP-targeting strategies in human cancer including RCC. In this review, the role of PTHrP in RCC tumorigenesis and its potential as a therapeutic target will be discussed.
Collapse
Affiliation(s)
- Carole Sourbier
- INSERM U727, Section of Renal Pharmacology and Physiopathology, School of Medicine, University Louis Pasteur, 67085 Strasbourg, France
| | | |
Collapse
|
2
|
Walther MM, Patel B, Choyke PL, Lubensky IA, Vocke CD, Harris C, Venzon D, Burtis WJ, Linehan WM. Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J Urol 1997; 158:733-9. [PMID: 9258070 DOI: 10.1097/00005392-199709000-00011] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE The role of nephrectomy in the management of hypercalcemia in metastatic renal carcinoma is not known. Hypercalcemia in patients with renal cell carcinoma frequently mimics primary hyperparathyroidism and has been attributed to tumor secretion of parathyroid hormone related protein. We determined the role of cytoreductive surgery in patients with metastatic renal cell carcinoma and hypercalcemia, identified factors that predict patient benefit from surgery, and evaluated the mechanisms of hypercalcemia in these patients. MATERIALS AND METHODS A total of 15 patients with metastatic renal cell carcinoma and hypercalcemia underwent metabolic and laboratory evaluation followed by nephrectomy. Post-operatively they were followed for changes in serum calcium levels. We selected 18 normocalcemic patients with metastatic renal cell carcinoma and 4 normocalcemic patients without renal cancer to serve as control groups for survival and parathyroid hormone related protein expression. RESULTS A decrease in serum calcium corrected for albumin occurred in 9 of 11 patients at 1 to 4 weeks after nephrectomy and in 7 of 12 patients at 5 to 16 weeks after nephrectomy. Clinical evaluation supported a parathyroid hormone related protein mechanism of hypercalcemia in 5 of 8 patients. Two patients had evidence of local osteolytic hypercalcemia and 1 had prostaglandin mediated hypercalcemia. CONCLUSIONS Nephrectomy temporarily ameliorated hypercalcemia in a subgroup of patients with metastatic renal cancer and hypercalcemia. Parathyroid hormone related protein expression was commonly found to be associated with hypercalcemia. Nonparathyroid hormone related protein mechanisms of hypercalcemia in renal carcinoma may be more common than previously thought.
Collapse
Affiliation(s)
- M M Walther
- Department of Radiology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Walther MM, Patel B, Choyke PL, Lubensky IA, Vocke CD, Harris C, Venzon D, Burtis WJ, Linehan WM. Hypercalcemia in Patients With Metastatic Renal Cell Carcinoma: Effect of Nephrectomy and Metabolic Evaluation. J Urol 1997. [DOI: 10.1016/s0022-5347(01)64303-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- McClellan M. Walther
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - Biren Patel
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - Peter L. Choyke
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - Irina A. Lubensky
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - Cathy D. Vocke
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - Cynthia Harris
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - David Venzon
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - William J. Burtis
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| | - W. Marston Linehan
- From the Urologic Oncology Section, Surgery Branch, Department of Radiology, Laboratory of Pathology and the Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Division of Endocrinology, West Haven Veterans Affairs Medical Center, West Haven, Connecticut
| |
Collapse
|
4
|
Dunbar ME, Wysolmerski JJ, Broadus AE. Parathyroid Hormone-Related Protein: From Hypercalcemia of Malignancy to Developmental Regulatory Molecule. Am J Med Sci 1996. [DOI: 10.1016/s0002-9629(15)41844-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Dunbar ME, Wysolmerski JJ, Broadus AE. Parathyroid hormone-related protein: from hypercalcemia of malignancy to developmental regulatory molecule. Am J Med Sci 1996; 312:287-94. [PMID: 8969618 DOI: 10.1097/00000441-199612000-00007] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Parathyroid hormone-related protein (PTHrP) was originally discovered because of its role in humoral hypercalcemia of malignancy (HHM), a common metabolic complication of many types of cancer. In HHM, PTHrP is released into the circulation by malignant cells and cross reacts with parathyroid hormone (PTH) receptors in bone and kidney, which results in hypercalcemia. In recent years, it has become clear that PTHrP is a normal product of many adult and fetal tissues where it appears to act in an autocrine and/or paracrine fashion to regulate organogenesis. This article explores the molecular evolution of PTHrP and how this understanding has begun to shed some light on the molecular mechanisms responsible for the biochemical manifestations of HHM. In addition, the normal biological function of PTHrP is discussed, with an emphasis on its role as a developmental regulatory molecule.
Collapse
Affiliation(s)
- M E Dunbar
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA
| | | | | |
Collapse
|
6
|
Wysolmerski JJ, McCaughern-Carucci JF, Daifotis AG, Broadus AE, Philbrick WM. Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Development 1995; 121:3539-47. [PMID: 8582268 DOI: 10.1242/dev.121.11.3539] [Citation(s) in RCA: 141] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Parathyroid hormone-related protein (PTHrP) was originally discovered as the tumor product that causes humoral hypercalcemia of malignancy. PTHrP is now known to be widely expressed in many normal fetal tissues where it may participate in the regulation of organogenesis. In this report, we document that overexpression of PTHrP in myoepithelial cells in the mammary glands of transgenic mice resulted in a form of breast hypoplasia characterized by a profound defect in branching morphogenesis of the developing mammary duct system. In addition, transgenic mice manifested a defect in lobuloalveolar development during pregnancy that seemed to be, in part, the consequence of an impaired ability to form terminal ducts in response to estrogen and progesterone stimulation. The effects of PTHrP on branching morphogenesis during breast development appeared to be the result of amino-terminal PTH-like sequences that signal through the PTH/PTHrP receptor, since overexpression of parathyroid hormone itself in the mammary glands of transgenic mice caused a similar development phenotype, and delivery of PTHrP (1–36) via locally implanted slow-release pellets impaired breast development in normal mice. These results suggest that PTHrP, which is a native product of mammary epithelial and myoepithelial cells may participate in normal breast development, perhaps as a locally secreted growth inhibitor.
Collapse
Affiliation(s)
- J J Wysolmerski
- Department of Medicine, Yale University School of Medicine, New Haven, CT 06516, USA
| | | | | | | | | |
Collapse
|
7
|
Wysolmerski JJ, Broadus AE. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annu Rev Med 1994; 45:189-200. [PMID: 8198376 DOI: 10.1146/annurev.med.45.1.189] [Citation(s) in RCA: 109] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Hypercalcemia is the most common metabolic complication of cancer. Malignancy-associated hypercalcemia (MAHC) can be divided into two syndromes, humoral hypercalcemia of malignancy (HHM) and local osteolytic hypercalcemia (LOH), based on whether a circulating hormone or local paracrine factors mediate accelerated bone resorption. Over the past decade, studies have shown that parathyroid hormone-related protein is the cause of the HHM syndrome, and recent data suggest that this protein may also play a paracrine role in some patients with local osteolytic hypercalcemia. Study of the regulation of parathyroid hormone-related protein gene expression is beginning to shed some light on the molecular mechanisms responsible for this common clinical problem.
Collapse
Affiliation(s)
- J J Wysolmerski
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510
| | | |
Collapse
|
8
|
Affiliation(s)
- T Schilling
- Department of Internal Medicine I-Endocrinology and Metabolism, University of Heidelberg, Germany
| |
Collapse
|
9
|
Holt E, Vasavada R, Bander N, Broadus A, Philbrick W. Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. J Biol Chem 1993. [DOI: 10.1016/s0021-9258(20)80772-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
10
|
Soifer N, Dee K, Insogna K, Burtis W, Matovcik L, Wu T, Milstone L, Broadus A, Philbrick W, Stewart A. Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell types. J Biol Chem 1992. [DOI: 10.1016/s0021-9258(19)37178-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
11
|
Burton PB, Knight DE. Parathyroid hormone-related peptide can regulate the growth of human lung cancer cells, and may form part of an autocrine TGF-alpha loop. FEBS Lett 1992; 305:228-32. [PMID: 1299622 DOI: 10.1016/0014-5793(92)80674-6] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Parathyroid hormone-related peptide (PTHrP) and transforming growth factor-alpha (TGF-alpha) were found to stimulate proliferation of human lung cancer cells (BEN-57). TGF-alpha stimulated PTHrP secretion from these cells. The polyclonal antisera raised against PTHrP significantly inhibited the growth of BEN-57 cells, and also the proliferation induced by TGF-alpha. Treatment of cells for up to 10 days with either a PTHrP receptor antagonist (PTHrP(7-34)) or PTHrP antiserum significantly inhibited the subsequent growth of these cells. We suggest that PTHrP may be a component of a complex autocrine loop involving TGF-alpha.
Collapse
Affiliation(s)
- P B Burton
- Division of Biomedical Sciences, Kings College, London, UK
| | | |
Collapse
|
12
|
Miyake Y, Yamaguchi K, Honda S, Nagasaki K, Tsuchihashi T, Mori M, Kimura S, Abe K. Production of parathyroid hormone-related protein in tumour xenografts in nude mice presenting with hypercalcaemia. Br J Cancer 1991; 63:252-6. [PMID: 1997102 PMCID: PMC1971791 DOI: 10.1038/bjc.1991.59] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
This study examined the pathophysiological role of parathyroid hormone-related protein (PTHrP) in humoral hypercalcaemia of malignancy (HHM). Seven human tumour xenografts were analysed in nude mice; five tumours (KEsC-2, oesophageal carcinoma; FA-6, pancreatic carcinoma; SEKI, melanoma; Lu-65A and Lu-61, lung carcinomas) were associated with hypercalcaemia and two tumours (MIA PaCa-2, pancreatic carcinoma; PLC/PRF/5, hepatocellular carcinoma) with normocalcaemia. Northern blot analyses, radioimmunoassay and bioassay confirmed the synthesis of PTHrP-like peptides by all five tumours associated with hypercalcaemia, but not by the two associated with normocalcaemia. These observations indicated a very close relationship between the production of PTHrP and the development of HHM. Gel filtration studies of three tumour tissue extracts revealed at least two different molecules with both PTHrP-like immunological and biological activities. One peak eluted at a position between PTHrP (1-141) and cytochrome C and the other at a position identical to cytochrome C. These results suggest that PTHrP molecules with a molecular size equal to or greater than cytochrome C participate as causative agents of HHM. All five tumour xenografts caused hypercalcaemia when grown to a size of 1.5 g in nude mice. Under cell culture conditions, four original cell lines, KEsC-2, FA-6, SEKI and Lu-65A secreted 450.0, 45.0, 3.6 and 3.0 pmol of immunoreactive PTHrP/1.5 x 10(9) cells (approximately equivalent to 1.5 g wet weight) 24 h-1 into their respective culture media. Since a subcutaneous infusion of 100 pmol 24 h-1 of PTHrP (1-34) into nude mice was sufficient to induce significant hypercalcaemia, we speculate that PTHrP alone released from tumour cells could induce hypercalcaemia at least in the case of KEsC-2, and possibly in FA-6. With regard to other tumours associated with hypercalcaemia, further examination of PTHrP and other compounds with bone-resorbing activity in these transplantable tumours is required to obtain a better understanding of this morbidity.
Collapse
|
13
|
Kao PC, Klee GG, Taylor RL, Heath H. Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. Mayo Clin Proc 1990; 65:1399-407. [PMID: 1700240 DOI: 10.1016/s0025-6196(12)62163-6] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We developed and validated a radioimmunoassay for circulating human parathyroid hormone-related peptide (PTHrP), based on a commercial antiserum to the synthetic 1-34 fragment of PTHrP, 125I-Tyr degrees-PTHrP(1-34) as radioligand, and prior extraction of the native peptide from plasma with C-2 cartridges. We determined immunoreactive PTHrP concentrations in plasma samples from 48 healthy persons (mean +/- SD, 3.1 +/- 1.0 pmol/liter; range, less than 2 to 5 pmol/liter), 8 patients with primary hyperparathyroidism, 36 patients with hypercalcemia and a concurrent malignant lesion, and 9 normocalcemic patients with cancer and increased serum levels of carcinoembryonic antigen or prostate-specific antigen. PTHrP was normal in samples from patients with primary hyperparathyroidism (3.2 +/- 1.1 pmol/liter), secondary hyperparathyroidism (2.5 +/- 1.3 pmol/liter), and cancer without hypercalcemia (2.4 +/- 1.0 pmol/liter). In contrast, plasma immunoreactive PTHrP levels were increased (6.0 to 85.0 pmol/liter) in 47% of patients with hypercalcemia and cancer of various types, with or without bone metastatic lesions. Large amounts of PTHrP were also found in conditioned medium from cultured human prostatic carcinoma cells. Thus, PTHrP may be a causative factor for hypercalcemia associated with a malignant lesion in at least half of the cases. Measurement of circulating PTHrP may be of differential diagnostic help in hypercalcemic states.
Collapse
Affiliation(s)
- P C Kao
- Section of Clinical Chemistry, Mayo Clinic, Rochester, MN 55905
| | | | | | | |
Collapse
|
14
|
Ikeda K, Lu C, Weir EC, Mangin M, Broadus AE. Regulation of parathyroid hormone-related peptide gene expression by cycloheximide. J Biol Chem 1990. [DOI: 10.1016/s0021-9258(19)39372-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
15
|
Burton PB, Moniz C, Knight DE. Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma. Biochem Biophys Res Commun 1990; 167:1134-8. [PMID: 2322262 DOI: 10.1016/0006-291x(90)90641-y] [Citation(s) in RCA: 78] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Parathyroid hormone related peptide (PTHrP) has been implicated in the cause of the hypercalcemia associated with a number of malignant tumours. The data presented here suggests that PTHrP (in addition to its known role of mediating hypercalcemia) may be involved in the autocrine regulation of growth of some tumours. Polyclonal PTHrP antiserum almost totally inhibited the growth of a human renal cell carcinoma cell line, known to secrete PTHrP, in vitro and growth was significantly inhibited by the competitive PTH antagonist PTH (3-34)NH2.
Collapse
Affiliation(s)
- P B Burton
- Division of Biomedical Sciences, Kings College, London, United Kingdom
| | | | | |
Collapse
|
16
|
Mehdizadeh S, Alaghband-Zadeh J, Gusterson B, Arlot M, Bradbeer JN, Loveridge N. Bone resorption and circulating PTH-like bioactivity in an animal model of hypercalcaemia of malignancy. Biochem Biophys Res Commun 1989; 161:1166-71. [PMID: 2742581 DOI: 10.1016/0006-291x(89)91364-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
An in vivo model of humoral hypercalcaemia of malignancy has been used to examine the role of circulating PTH-like bioactivity in the development of bone resorption and hypercalcaemia. After inoculation of cells from a renal carcinoma cell line into nude mice, circulating PTH-like bioactivity as measured by the sensitive renal and metatarsal cytochemical bioassays for PTH was elevated in only 18% and 53% of the mice respectively. Bone resorption was elevated in all the mice investigated irrespective of the level of PTH-like bioactivity. Thus, in this model, while the circulating PTH-like moiety is more potent when acting on bone, it did not correlate with the degree of bone resorption suggesting that it may not be the sole cause of the hypercalcaemia.
Collapse
Affiliation(s)
- S Mehdizadeh
- Dept of Chemical Pathology, Charing Cross Hospital, London, UK
| | | | | | | | | | | |
Collapse
|
17
|
Abstract
Hypercalcaemia in malignancy is a major clinical problem. It contributes significantly to morbidity and mortality and can present difficult diagnostic and management dilemmas. Direct bony invasion by tumour cells rather than humorally mediated hypercalcaemia is probably the most common cause of malignant hypercalcaemia. Yet even in this situation the mechanism of bone resorption or the reason that the normal homeostatic mechanisms cannot cope with the calcium load are poorly understood. It is likely that the humoral and paracrine factors produced by tumours which result in hypercalcaemia or in osteosclerotic bone metastases, are interposing themselves into the normal regulatory processes and deranging them. Humoral hypercalcaemia of malignancy is an important model for studying these questions, and it also provides some insight into the normal regulation of bone turnover. This review will examine the animal models and human syndromes of malignant hypercalcaemia and show how animal models, although helpful, fail to delineate the relative importance of the various potential humoral factors. A most interesting recent development in this area is the description of a new hormone, the parathyroid hormone-related peptide, which may explain many of the cases of humoral hypercalcaemia of malignancy. It is also a useful model with multiple sites of action within the bone and calcium homeostatic process. The active hormonal form of vitamin D3, 1,25-dihydroxyvitamin D3, may also be involved in a small proportion of cases, but again it is a useful model of some of the factors that may operate. Of considerable interest are the tumour derived factors, such as the transforming growth factors, and the cytokines, such as tumour necrosis factors, interleukins, and haemopoietic colony stimulating factors. Prostanoids are seldom of major importance, but may be important in certain tumour types. Osteosclerotic metastases, although seldom associated with hypercalcaemia, may provide insight into osteoblast regulating factors. Treatment of hypercalcaemia is discussed to show ways in which response to treatment may shed light on underlying pathophysiological mechanisms. Most effective treatments have many potential modes of action, and further study of the interactions of these agents and tumour types may help to unravel some of the enigmas in this human syndrome. The major advances in this complex problem involve the realisation of the necessity of multiple sites of action, including renal calcium handling as well as relative increases in bone resorption and/or intestinal calcium absorption.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- P J Kelly
- Garvan Institute of Medical Research, St Vincents Hospital, Sydney, NSW, Australia
| | | |
Collapse
|
18
|
Abstract
The approach to the patient with hypercalcemia requires a solid understanding of the principles of calcium homeostasis, knowledge of its differential diagnosis and the associated pathophysiologies, and the clinical judgment to know when and how to administer appropriate therapy. Recent advances in our understanding of the regulation of mineral metabolism have led to new insights into these areas and have improved our ability to deal with this rather common clinical entity. The purpose of this monograph is to give a current view of hypercalcemia as it is appreciated in the outpatient and the inpatient setting. It is designed to focus the evaluation of the hypercalcemic patient in a way that is both expedient and accurate as well as to take advantage of available therapies. A summary of the underlying physiological principles of calcium homeostasis is followed by a consideration of the complete differential diagnosis of hypercalcemia. The two most important causes of hypercalcemia, primary hyperparathyroidism and malignancy, are emphasized. Signs and symptoms of hypercalcemia are discussed with particular attention to those factors that are influential in accentuating or masking these features. Finally, an approach to the therapy of hypercalcemia is presented within a pathophysiological framework.
Collapse
Affiliation(s)
- J P Bilezikian
- College of Physicians and Surgeons, Columbia University, New York, New York
| |
Collapse
|
19
|
Weir EC, Centrella M, Matus RE, Brooks ML, Wu T, Insogna KL. Adenylate cyclase-stimulating, bone-resorbing and B TGF-like activities in canine apocrine cell adenocarcinoma of the anal sac. Calcif Tissue Int 1988; 43:359-65. [PMID: 3146425 DOI: 10.1007/bf02553279] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Canine apocrine cell adenocarcinoma of the anal sac (APO-AS) is a spontaneously occurring tumor that causes humorally mediated hypercalcemia in 90% of cases. To further define the nature of the responsible mediator in APO-AS, we examined tumor extracts from five APO-AS and four control tumors for adenylate cyclase-stimulating activity (ACSA). All extracts from APO-AS contained potent ACSA, whereas the four control tumors did not. The ACSA extracted from one tumor demonstrated a dose response curve parallel to that of synthetic bovinePTH-(1-34) and was 80% inhibited by Nle8,18,Tyr34 bPTH-(3-34)amide at a concentration of 10(-5) M. Extracts from three APO-AS and three control tumors were also examined for in vitro bone-resorbing activity (BRA). All APO-AS contained significant BRA, stimulating resorption 1.47 to 2.13-fold over basal, whereas none of the control tumors stimulated resorption. Purification of one extract using C18 reverse-phase high pressure liquid chromatography (RP-HPLC) resulted in a single sharp peak of ACSA which was 400-fold purified compared with the initial extract. This pool also contained significant bone-resorbing activity, whereas none of the adjacent pools did. Purification of a second extract using sequential CN and C18 RP-HPLC followed by size exclusion HPLC resulted in material that was at least 10,000-fold purified, and showed co-purification of ACSA and B TGF-like activity.
Collapse
Affiliation(s)
- E C Weir
- Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut 06510
| | | | | | | | | | | |
Collapse
|
20
|
Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med 1988; 319:556-63. [PMID: 3043221 DOI: 10.1056/nejm198809013190906] [Citation(s) in RCA: 209] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- A E Broadus
- Department of Internal Medicine, Yale University, New Haven, Conn
| | | | | | | | | | | | | |
Collapse
|
21
|
Ikeda K, Mangin M, Dreyer BE, Webb AC, Posillico JT, Stewart AF, Bander NH, Weir EC, Insogna KL, Broadus AE. Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. J Clin Invest 1988; 81:2010-4. [PMID: 2454953 PMCID: PMC442656 DOI: 10.1172/jci113551] [Citation(s) in RCA: 91] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The syndrome of humoral hypercalcemia of malignancy (HHM) appears to be mediated in many instances by a parathyroid hormone-like peptide, which has recently been purified, sequenced, and cloned. Using a probe representing the coding region of the human PTH-like peptide, we examined by Northern analysis poly (A)+ RNA from a variety of human and animal tumors associated with HHM. Hybridizing transcripts were identified in mRNA from each of 12 human and each of four animal HHM-associated tumors, with a complex hybridization pattern observed in the human mRNAs and a relatively simple pattern observed in the animal mRNAs. Poly (A)+ RNA prepared from tumors of similar histological types unassociated with HHM failed to hybridize with the probe. Messenger RNA-dependent biological activity from the animal tumors was entirely eliminated in a hybridization-arrest experiment using a complementary oligonucleotide spanning the region of homology between human PTH and the PTH-like peptide. These findings indicate that the PTH-like peptide is associated with the syndrome of HHM in a wide spectrum of tumor types from a variety of mammalian species and that the PTH-like sequence in the proximal amino terminus of the peptide is highly conserved.
Collapse
Affiliation(s)
- K Ikeda
- Department of Medicine, Yale University, New Haven, Connecticut 06511
| | | | | | | | | | | | | | | | | | | |
Collapse
|